by James Smith
The Lancet Infectious Diseases, Vol. 17, No. 2, pp. 128–130, February 2017
On Oct 10, 2015, Médecins Sans Frontières (MSF) rejected Pfizer’s proposed donation of 1 million doses of its branded pneumococcal conjugate vaccine (PCV). The news caused a stir in the global health community; after all, free essential health goods might be considered something to be celebrated. This decision represents the latest development in a prolonged advocacy campaign spearheaded by MSF, which aims to reduce the cost of PCV, and presents a timely opportunity to examine the case for vaccine donations.